Intepirdine

Intepirdine is a pharmaceutical drug that was under development for the treatment of Alzheimer's disease and other neurodegenerative disorders. It was developed by Axovant Sciences, a biopharmaceutical company that specializes in the development of treatments for neurodegenerative diseases.

History[edit | edit source]

Intepirdine was initially developed by GlaxoSmithKline, a British multinational pharmaceutical company. In 2014, the development and commercialization rights for the drug were acquired by Axovant Sciences.

Mechanism of Action[edit | edit source]

Intepirdine is a 5-HT6 receptor antagonist. The 5-HT6 receptor is a subtype of the 5-HT receptor that binds the endogenous neurotransmitter serotonin. It is thought that blocking this receptor can enhance the release of acetylcholine, a neurotransmitter that is often deficient in people with Alzheimer's disease.

Clinical Trials[edit | edit source]

Intepirdine has undergone several clinical trials to assess its safety and efficacy in treating Alzheimer's disease. However, in 2017, Axovant announced that the drug had failed to meet its primary endpoints in a Phase III clinical trial.

Future Development[edit | edit source]

Despite the failure of the Phase III trial, Axovant has stated that it will continue to explore other potential uses for intepirdine, including its use in combination with other drugs.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.